Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY-NC-NDJTO clinical and research reports

Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC — Primary Analysis of the ATORG-003 Phase 2 Trial

  • Aaron C. Tan1
  • Tae Min Kim2
  • Siqin Zhou3
  • Yueh Ni Lim4
  • Gwo Fuang Ho5
  • Lye Mun Tho6
  • Thanyanan Baisamut7
  • Naiyarat Prasongsook8
  • Suee Lee9
  • Sze Huey Tan3
  • Dong-Wan Kim2
  • Tony Mok10
2 more authors
  • Daniel S.W. Tan1
  • Herbert H. Loong10
10 affiliations
  1. 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  2. 2Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
  3. 3Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore
  4. 4Clinical Oncology Department, Sarawak General Hospital, Kuching, Malaysia
  5. 5Clinical Oncology Department, University Malaya Medical Centre, Kuala Lumpur, Malaysia
  6. 6Cancer Specialist Centre, Beacon Hospital, Kuala Lumpur, Malaysia
  7. 7Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand
  8. 8Division of Oncology, Phramongkutklao Hospital, Bangkok, Thailand
  9. 9Department of Hemato-Oncology, Dong-A University Medical Center, Busan, Republic of Korea
  10. 10Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, Hong Kong PRC
Read full textPDFCite

Related

  1. Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries
    Ana Caroline Zimmer Gelatti, Eldsamira Mascarenhas, Guilherme Harada +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  2. Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients
    Haruhiko Yamazaki, Nobuyasu Suganuma, Mei Kadoya +3
    Endocrine JournalPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE
  3. Cost-effectiveness of inavolisib plus palbociclib/fulvestrant versus palbociclib/fulvestrant for PIK3CA-mutated advanced breast cancer in China
    Zuojuan Xiang, Xiaojuan Chen, Ling Ma
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefDOAJ
  4. Chinese medicine combined with EGFR-TKIs in EGFR-mutated advanced NSCLC: a meta-analysis of efficacy and safety
    Xiaohong Li, Die Qian, Shuai Liu +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyPMCCrossrefEurope PMC
  5. Central nervous system efficacy of third generation vs. first generation EGFR-TKIs in the first line treatment for EGFR-mutated non-small cell lung cancer with central nervous system metastases: a systematic review and meta-analysis of phase 3 randomized controlled trials
    Jiongli Gan, Shaofeng Zhu, Yan Fang +3
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{tan2026dacomitinib,
  title = {{Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC — Primary Analysis of the ATORG-003 Phase 2 Trial}},
  author = {Aaron C. Tan and Tae Min Kim and Siqin Zhou and Yueh Ni Lim and Gwo Fuang Ho and Lye Mun Tho and Thanyanan Baisamut and Naiyarat Prasongsook and Suee Lee and Sze Huey Tan and Dong-Wan Kim and Tony Mok and Daniel S.W. Tan and Herbert H. Loong},
  journal = {JTO clinical and research reports},
  year = {2026},
  month = jun,
  url = {https://europepmc.org/article/PMC/PMC13658125},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC — Primary Analysis of the ATORG-003 Phase 2 Trial
AU  - Aaron C. Tan
AU  - Tae Min Kim
AU  - Siqin Zhou
AU  - Yueh Ni Lim
AU  - Gwo Fuang Ho
AU  - Lye Mun Tho
AU  - Thanyanan Baisamut
AU  - Naiyarat Prasongsook
AU  - Suee Lee
AU  - Sze Huey Tan
AU  - Dong-Wan Kim
AU  - Tony Mok
AU  - Daniel S.W. Tan
AU  - Herbert H. Loong
PY  - 2026
DA  - 2026/06/01
JO  - JTO clinical and research reports
UR  - https://europepmc.org/article/PMC/PMC13658125
SN  - 2666-3643
ER  -